3-(1H-吡唑-1-甲基)苯甲醛 | 78425-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(1H-吡唑-1-甲基)苯甲醛
• 英文名称: 3-(1H-pyrazol-1-ylmethyl)benzaldehyde
• 英文别名: 3-(pyrazol-1-ylmethyl)benzaldehyde
• CAS: 78425-11-3
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD08059836
• 分子量: 186.213
• InChiKey: VKSSMLBTEXYZDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  L-缬氨醇 、 3-(1H-吡唑-1-甲基)苯甲醛 在 碘 、 potassium carbonate 作用下， 以 叔丁醇 为溶剂， 反应 18.5h， 以36.1%的产率得到(4S)-4-propan-2-yl-2-[3-(pyrazol-1-ylmethyl)phenyl]-4,5-dihydro-1,3-oxazole
  参考文献：
  名称：

  Unsymmetrical, oxazolinyl-containing achiral and chiral NCN pincer ligand precursors and their complexes with palladium(II)

  摘要：

  The unsymmetrical, achiral and chiral NCN pincer ligand precursors (3a-3d) with oxazoline and pyrazole as N donors as well as (3e) which has oxazolinyl and amino group have been synthesized in a facile manner in four steps starting from commercially available isophthalaldehyde. Direct C2 metallation of the precursors (3a-3e) with Pd(OAc)(2) in refluxing HOAc, followed by treatment with LiCl at room temperature provided convenient access to the corresponding pincer palladium(II) complexes (4a-4e). The molecular structure of complex 4e has been determined by X-ray single-crystal diffraction. The obtained Pd complexes exhibited good activities in the Suzuki reactions of aryl bromides and activated aryl chlorides with phenylboronic acid. (C) 2009 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2009.09.031
• 作为产物：
  描述：

  吡唑 、 3-(溴甲基)苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以48.1%的产率得到3-(1H-吡唑-1-甲基)苯甲醛
  参考文献：
  名称：

  Unsymmetrical, oxazolinyl-containing achiral and chiral NCN pincer ligand precursors and their complexes with palladium(II)

  摘要：

  The unsymmetrical, achiral and chiral NCN pincer ligand precursors (3a-3d) with oxazoline and pyrazole as N donors as well as (3e) which has oxazolinyl and amino group have been synthesized in a facile manner in four steps starting from commercially available isophthalaldehyde. Direct C2 metallation of the precursors (3a-3e) with Pd(OAc)(2) in refluxing HOAc, followed by treatment with LiCl at room temperature provided convenient access to the corresponding pincer palladium(II) complexes (4a-4e). The molecular structure of complex 4e has been determined by X-ray single-crystal diffraction. The obtained Pd complexes exhibited good activities in the Suzuki reactions of aryl bromides and activated aryl chlorides with phenylboronic acid. (C) 2009 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2009.09.031

文献信息

• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：MARS INC

  公开号：WO2011133653A1

  公开（公告）日：2011-10-27

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。
• INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Van Zandt Michael

  公开号：US20120083469A1

  公开（公告）日：2012-04-05

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据公式I和公式II的化合物是Arginase I和II活性的有效抑制剂：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，D，M，X和Y的定义如规范中所述。该发明还提供了这些化合物的制药组合物和使用它们治疗或预防与Arginase活性相关的疾病或病况的方法。
• US9040703B2
  申请人：——

  公开号：US9040703B2

  公开（公告）日：2015-05-26
• US9994594B2
  申请人：——

  公开号：US9994594B2

  公开（公告）日：2018-06-12